Evidence of epigenetic tags in cardiac fibrosis

Journal of Cardiology

Volumn 69, Issue 2, 2017, Pages 401-408

  Grimaldi, Vincenzo ^a,b   De Pascale, Maria Rosaria ^a,b   Zullo, Alberto ^b,c   Soricelli, Andrea ^d,e   Infante, Teresa ^d   Mancini, Francesco Paolo ^b   Napoli, Claudio ^a,d  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF SANNIO   (Italy)

^c CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^d IRCCS SDN   (Italy)

^e UNIVERSITY OF NAPLES PARTHENOPE   (Italy)

Author keywords

Anti miRNA; Cardiac fibrosis; Dietary epigenetic compounds; DNA methylation; Histone deacetylase inhibitor

Indexed keywords

AZACITIDINE; DECITABINE; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; LONG UNTRANSLATED RNA; MICRORNA; MOCETINOSTAT; RAS PROTEIN; RESVERATROL; TRICHOSTATIN A; ENZYME INHIBITOR; GENETIC MARKER; HISTONE DEACETYLASE;

CARDIAC MUSCLE CELL; CELL DIFFERENTIATION; DISEASE COURSE; DNA METHYLATION; ENZYME ACTIVITY; ENZYME INHIBITION; EPIGENETICS; EXTRACELLULAR MATRIX; FIBROBLAST; HEART FIBROBLAST; HEART MUSCLE FIBROSIS; HISTONE MODIFICATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MYOFIBROBLAST; REVIEW; TUMOR SUPPRESSOR GENE; ANIMAL; CARDIAC MUSCLE; CARDIOMYOPATHY; DIET; DRUG EFFECTS; FIBROSIS; GENETIC EPIGENESIS; GENETIC MARKER; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; UPREGULATION;

ANIMALS; CARDIOMYOPATHIES; CELL DIFFERENTIATION; DIET; DISEASE PROGRESSION; DNA METHYLATION; ENZYME INHIBITORS; EPIGENESIS, GENETIC; FIBROBLASTS; FIBROSIS; GENETIC MARKERS; HISTONE DEACETYLASES; HUMANS; MICRORNAS; MYOCARDIUM; MYOFIBROBLASTS; RNA, LONG NONCODING; UP-REGULATION;

EID: 85006345832     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2016.10.004     Document Type: Review

References (97)

1. [1] Kong, P., Christia, P., Frangogiannis, N.G., The pathogenesis of cardiac fibrosis. Cell Mol Life Sci 71 (2014), 549–574.
2. [2] Zeisberg, M., Kalluri, R., Cellular mechanisms of tissue fibrosis. Common and organ-specific mechanisms associated with tissue fibrosis. Am J Physiol Cell Physiol 304 (2013), C216–C225.
3. [3] Stratton, M.S., McKinsey, T.A., Epigenetic regulation of cardiac fibrosis. J Mol Cell Cardiol 92 (2016), 206–213.
4. [4] Napoli, C., Grimaldi, V., De Pascale, M.R., Sommese, L., Infante, T., Soricelli, A., Novel epigenetic-based therapies useful in cardiovascular medicine. World J Cardiol 8 (2016), 211–219.
5. [5] Schiano, C., Vietri, M.T., Grimaldi, V., Picascia, A., Pascale, M.R., Napoli, C., Epigenetic-related therapeutic challenges in cardiovascular disease. Trends Pharmacol Sci 36 (2015), 226–235.
6. [6] Pasipoularides, A., Linking genes to cardiovascular diseases: gene action and gene–environment interactions. J Cardiovasc Transl Res 8 (2015), 506–527.
7. [7] Lee, H.S., Impact of maternal diet on the epigenome during in utero life and the developmental programming of diseases in childhood and adulthood. Nutrients 7 (2015), 9492–9507.
8. [8] Yu, L.M., Xu, Y., Epigenetic regulation in cardiac fibrosis. World J Cardiol 7 (2015), 784–791.
9. [9] Cavalera, M., Wang, J., Frangogiannis, N.G., Obesity, metabolic dysfunction, and cardiac fibrosis: pathophysiological pathways, molecular mechanisms, and therapeutic opportunities. Transl Res 164 (2014), 323–335.
10. [10] Shinohara, D., Matsushita, S., Yamamoto, T., Inaba, H., Kuwaki, K., Shimada, A., Amano, A., Reduction of c-kit positive cardiac stem cells in patients with atrial fibrillation. J Cardiol, 2016 [Epub ahead of print].
11. [11] Pinto, A.R., Ilinykh, A., Ivey, M.J., Kuwabara, J.T., D'Antoni, M.L., Debuque, R., Chandraker, A., Wang, L., Arora, K., Rosenthal, N.A., Tallquist, M.D., Revisiting cardiac cellular composition. Circ Res 118 (2016), 400–409.
12. [12] Travers, J.G., Kamal, F.A., Robbins, J., Yutzey, K.E., Blaxall, B.C., Cardiac fibrosis: the fibroblast awakens. Circ Res 118 (2016), 1021–1040.
13. [13] Souders, C.A., Bowers, S.L., Baudino, T.A., Cardiac fibroblast: the renaissance cell. Circ Res 105 (2009), 1164–1176.
14. [14] Drobnik, J., Owczarek, K., Piera, L., Tosik, D., Olczak, S., Ciosek, J., Hrabec, E., Melatonin-induced augmentation of collagen deposition in cultures of fibroblasts and myofibroblasts is blocked by luzindole – a melatonin membrane receptors inhibitor. Pharmacol Rep 65 (2013), 642–649.
15. [15] Hinz, B., Phan, S.H., Thannickal, V.J., Prunotto, M., Desmoulière, A., Varga, J., De Wever, O., Mareel, M., Gabbiani, G., Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. Am J Pathol 180 (2012), 1340–1355.
16. [16] Zeisberg, E.M., Tarnavski, O., Zeisberg, M., Dorfman, A.L., McMullen, J.R., Gustafsson, E., Chandraker, A., Yuan, X., Pu, W.T., Roberts, A.B., Neilson, E.G., Sayegh, M.H., Izumo, S., Kalluri, R., Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 13 (2007), 952–961.
17. [17] Ghosh, A.K., Nagpal, V., Covington, J.W., Michaels, M.A., Vaughan, D.E., Molecular basis of cardiac endothelial-to-mesenchymal transition (EndMT): differential expression of microRNAs during EndMT. Cell Signal 24 (2012), 1031–1036.
18. [18] Lishnevsky, M., Haudek, S.B., Epigenetic regulation of fibrocyte differentiation. J Mol Cell Cardiol 69 (2014), 85–87.
19. [19] Xu, X., Tan, X., Tampe, B., Nyamsuren, G., Liu, X., Maier, L.S., Sossalla, S., Kalluri, R., Zeisberg, M., Hasenfuss, G., Zeisberg, E.M., Epigenetic balance of aberrant Rasal1 promoter methylation and hydroxymethylation regulates cardiac fibrosis. Cardiovasc Res 105 (2015), 279–291.
20. [20] Xu, X., Tan, X., Hulshoff, M.S., Wilhelmi, T., Zeisberg, M., Zeisberg, E.M., Hypoxia-induced endothelial-mesenchymal transition is associated with RASAL1 promoter hypermethylation in human coronary endothelial cells. FEBS Lett 590 (2016), 1222–1233.
21. [21] Watson, C.J., Collier, P., Tea, I., Neary, R., Watson, J.A., Robinson, C., Phelan, D., Ledwidge, M.T., McDonald, K.M., McCann, A., Sharaf, O., Baugh, J.A., Hypoxia-induced epigenetic modifications are associated with cardiac tissue fibrosis and the development of a myofibroblast-like phenotype. Adv Hum Mol Genet 23 (2014), 2176–2188.
22. [22] Tao, H., Yang, J.J., Chen, Z.W., Xu, S.S., Zhou, X., Zhan, H.Y., Shi, K.H., DNMT3A silencing RASSF1A promotes cardiac fibrosis through upregulation of ERK1/2. Toxicology 323 (2014), 42–50.
23. [23] Watson, C.J., Horgan, S., Neary, R., Glezeva, N., Tea, I., Corrigan, N., McDonald, K., Ledwidge, M., Baugh, J., Epigenetic therapy for the treatment of hypertension-induced cardiac hypertrophy and fibrosis. J Cardiovasc Pharmacol Ther 21 (2016), 127–137.
24. [24] Michels, K.B., Binder, A.M., Dedeurwaerder, S., Epstein, C.B., Greally, J.M., Gut, I., Houseman, E.A., Izzi, B., Kelsey, K.T., Meissner, A., Milosavljevic, A., Siegmund, K.D., Bock, C., Irizarry, R.A., Recommendations for the design and analysis of epigenome-wide association studies. Nat Methods 10 (2013), 949–955.
25. [25] Kao, Y.H., Liou, J.P., Chung, C.C., Lien, G.S., Kuo, C.C., Chen, S.A., Chen, Y.J., Histone deacetylase inhibition improved cardiac functions with direct antifibrotic activity in heart failure. Int J Cardiol 168 (2013), 4178–4183.
26. [26] Xie, M., Hill, J.A., HDAC-dependent ventricular remodeling. Trends Cardiovasc Med 23 (2013), 229–235.
27. [27] Pang, M., Zhuang, S., Histone deacetylase: a potential therapeutic target for fibrotic disorders. J Pharmacol Exp Ther 335 (2010), 266–272.
28. [28] Lee, T.M., Lin, M.S., Chang, N.C., Inhibition of histone deacetylase on ventricular remodeling in infarcted rats. Am J Physiol Heart Circ Physiol 293 (2007), H968–H977.
29. [29] Kang, S.H., Seok, Y.M., Song, M.J., Lee, H.A., Kurz, T., Kim, I., Histone deacetylase inhibition attenuates cardiac hypertrophy and fibrosis through acetylation of mineralocorticoid receptor in spontaneously hypertensive rats. Mol Pharmacol 87 (2015), 782–791.
30. [30] Tao, H., Shi, K.H., Yang, J.J., Huang, C., Zhan, H.Y., Li, J., Histone deacetylases in cardiac fibrosis: current perspectives for therapy. Cell Signal 26 (2014), 521–527.
31. [31] Eom, G.H., Kook, H., Role of histone deacetylase 2 and its posttranslational modifications in cardiac hypertrophy. BMB Rep 48 (2015), 131–138.
32. [32] Trivedi, C.M., Luo, Y., Yin, Z., Zhang, M., Zhu, W., Wang, T., Floss, T., Goettlicher, M., Noppinger, P.R., Wurst, W., Ferrari, V.A., Abrams, C.S., Gruber, P.J., Epstein, J.A., Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity. Nat Med 13 (2007), 324–331.
33. [33] Williams, S.M., Golden-Mason, L., Ferguson, B.S., Schuetze, K.B., Cavasin, M.A., Demos-Davies, K., Yeager, M.E., Stenmark, K.R., McKinsey, T.A., Class I HDACs regulate angiotensin II-dependent cardiac fibrosis via fibroblasts and circulating fibrocytes. J Mol Cell Cardiol 67 (2014), 112–125.
34. [34] Tao, H., Yang, J.J., Hu, W., Shi, K.H., Li, J., HDAC6 promotes cardiac fibrosis progression through suppressing RASSF1A expression. Cardiology 133 (2016), 18–26.
35. [35] Nural-Guvener, H.F., Zakharova, L., Nimlos, J., Popovic, S., Mastroeni, D., Gaballa, M.A., HDAC class I inhibitor, mocetinostat, reverses cardiac fibrosis in heart failure and diminishes CD90+ cardiac myofibroblast activation. Fibrogenesis Tissue Repair, 7, 2014, 10.
36. [36] Nural-Guvener, H., Zakharova, L., Feehery, L., Sljukic, S., Gaballa, M., Anti-fibrotic effects of class I HDAC inhibitor, mocetinostat is associated with IL-6/Stat3 signaling in ischemic heart failure. Int J Mol Sci 16 (2015), 11482–11499.
37. [37] Liu, F., Levin, M.D., Petrenko, N.B., Lu, M.M., Wang, T., Yuan, L.J., Stout, A.L., Epstein, J.A., Patel, V.V., Histone-deacetylase inhibition reverses atrial arrhythmia inducibility and fibrosis in cardiac hypertrophy independent of angiotensin. J Mol Cell Cardiol 45 (2008), 715–723.
38. [38] Shen, T., Ding, L., Ruan, Y., Qin, W., Lin, Y., Xi, C., Lu, Y., Dou, L., Zhu, Y., Cao, Y., Man, Y., Bian, Y., Wang, S., Xiao, C., Li, J., SIRT1 functions as an important regulator of estrogen-mediated cardiomyocyte protection in angiotensin II-induced heart hypertrophy. Oxid Med Cell Longev, 2014, 2014, 713894.
39. [39] Rizk, S.M., El-Maraghy, S.A., Nassar, N.N., A novel role for SIRT-1 in L-arginine protection against STZ induced myocardial fibrosis in rats. PLOS ONE, 9, 2014, e114560.
40. [40] Tian, K., Liu, Z., Wang, J., Xu, S., You, T., Liu, P., Sirtuin-6 inhibits cardiac fibroblasts differentiation into myofibroblasts via inactivation of nuclear factor κB signaling. Transl Res 165 (2015), 374–386.
41. [41] Sundaresan, N.R., Gupta, M., Kim, G., Rajamohan, S.B., Isbatan, A., Gupta, M.P., Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice. J Clin Invest 119 (2009), 2758–2771.
42. [42] Chen, T., Li, J., Liu, J., Li, N., Wang, S., Liu, H., Zeng, M., Zhang, Y., Bu, P., Activation of SIRT3 by resveratrol ameliorates cardiac fibrosis and improves cardiac function via the TGF-β/Smad3 pathway. Am J Physiol Heart Circ Physiol 308 (2015), H424–H434.
43. [43] Yu, L., Yang, G., Weng, X., Liang, P., Li, L., Li, J., Fan, Z., Tian, W., Wu, X., Xu, H., Fang, M., Ji, Y., Li, Y., Chen, Q., Xu, Y., Histone methyltransferase SET1 mediates angiotensin II-induced endothelin-1 transcription and cardiac hypertrophy in mice. Arterioscler Thromb Vasc Biol 35 (2015), 1207–1217.
44. [44] Weng, X., Yu, L., Liang, P., Li, L., Dai, X., Zhou, B., Wu, X., Xu, H., Fang, M., Chen, Q., Xu, Y., A crosstalk between chromatin remodeling and histone H3K4 methyltransferase complexes in endothelial cells regulates angiotensin II-induced cardiac hypertrophy. J Mol Cell Cardiol 82 (2015), 48–58.
45. [45] Piccoli, M.T., Bär, C., Thum, T., Non-coding RNAs as modulators of the cardiac fibroblast phenotype. J Mol Cell Cardiol 92 (2016), 75–81.
46. [46] Tao, H., Yang, J.J., Hu, W., Shi, K.H., Deng, Z.Y., Li, J., Noncoding RNA as regulators of cardiac fibrosis: current insight and the road ahead. Pflugers Arch, 2016 [Epub ahead of print].
47. [47] Beaumont, J., López, B., Hermida, N., Schroen, B., San José, G., Heymans, S., Valencia, F., Gómez-Doblas, J.J., De Teresa, E., Díez, J., González, A., MicroRNA-122 down-regulation may play a role in severe myocardial fibrosis in human aortic stenosis through TGF-β1 up-regulation. Clin Sci (Lond) 126 (2014), 497–506.
48. [48] Abonnenc, M., Nabeebaccus, A.A., Mayr, U., Barallobre-Barreiro, J., Dong, X., Cuello, F., Sur, S., Drozdov, I., Langley, S.R., Lu, R., Stathopoulou, K., Didangelos, A., Yin, X., Zimmermann, W.H., Shah, A.M., et al. Extracellular matrix secretion by cardiac fibroblasts: role of microRNA-29b and microRNA-30c. Circ Res 113 (2013), 1138–1147.
49. [49] He, Y., Huang, C., Lin, X., Li, J., MicroRNA-29 family, a crucial therapeutic target for fibrosis diseases. Biochimie 95 (2013), 1355–1359.
50. [50] Kumarswamy, R., Volkmann, I., Jazbutyte, V., Dangwal, S., Park, D.H., Thum, T., Transforming growth factor-β-induced endothelial-to-mesenchymal transition is partly mediated by microRNA-21. Arterioscler Thromb Vasc Biol 32 (2012), 361–369.
51. [51] Bang, C., Batkai, S., Dangwal, S., Gupta, S.K., Foinquinos, A., Holzmann, A., Just, A., Remke, J., Zimmer, K., Zeug, A., Ponimaskin, E., Schmiedl, A., Yin, X., Mayr, M., Halder, R., et al. Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy. J Clin Invest 124 (2014), 2136–2146.
52. [52] Roy, S., Khanna, S., Hussain, S.R., Biswas, S., Azad, A., Rink, C., Gnyawali, S., Shilo, S., Nuovo, G.J., Sen, C.K., MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc Res 82 (2009), 21–29.
53. [53] Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M., Galuppo, P., Just, S., Rottbauer, W., Frantz, S., Castoldi, M., Soutschek, J., Koteliansky, V., Rosenwald, A., Basson, M.A., et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456 (2008), 980–984.
54. [54] Wang, K., Liu, F., Zhou, L.Y., Long, B., Yuan, S.M., Wang, Y., Liu, C.Y., Sun, T., Zhang, X.J., Li, P.F., A long noncoding RNA, CHRF regulates cardiac hypertrophy by targeting miR-489. Circ Res 114 (2014), 1377–1388.
55. [55] Wang, J., Huang, W., Xu, R., Nie, Y., Cao, X., Meng, J., Xu, X., Hu, S., Zheng, Z., MicroRNA-24 regulates cardiac fibrosis after myocardial infarction. J Cell Mol Med 16 (2012), 2150–2160.
56. [56] Zhong, C., Wang, K., Liu, Y., Lv, D., Zheng, B., Zhou, Q., Sun, Q., Chen, P., Ding, S., Xu, Y., Huang, H., MiR-19b controls cardiac fibroblast proliferation and migration. J Cell Mol Med, 2016 [Epub ahead of print].
57. [57] Duisters, R.F., Tijsen, A.J., Schroen, B., Leenders, J.J., Lentink, V., van der Made, I., Herias, V., van Leeuwen, R.E., Schellings, M.W., Barenbrug, P., Maessen, J.G., Heymans, S., Pinto, Y.M., Creemers, E.E., MiR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ Res 104 (2009), 170–178.
58. [58] Muraoka, N., Yamakawa, H., Miyamoto, K., Sadahiro, T., Umei, T., Isomi, M., Nakashima, H., Akiyama, M., Wada, R., Inagawa, K., Nishiyama, T., Kaneda, R., Fukuda, T., Takeda, S., Tohyama, S., et al. MiR-133 promotes cardiac reprogramming by directly repressing Snai1 and silencing fibroblast signatures. EMBO J 33 (2014), 1565–1581.
59. [59] Castoldi, G., Di Gioia, C.R., Bombardi, C., Catalucci, D., Corradi, B., Gualazzi, M.G., Leopizzi, M., Mancini, M., Zerbini, G., Condorelli, G., Stella, A., MiR-133a regulates collagen 1A1: potential role of miR-133a in myocardial fibrosis in angiotensin II-dependent hypertension. J Cell Physiol 227 (2012), 850–856.
60. [60] Matkovich, S.J., Wang, W., Tu, Y., Eschenbacher, W.H., Dorn, L.E., Condorelli, G., Diwan, A., Nerbonne, J.M., Dorn, G.W. 2nd, MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts. Circ Res 106 (2010), 166–175.
61. [61] Chen, S., Puthanveetil, P., Feng, B., Matkovich, S.J., Dorn, G.W. 2nd, Chakrabarti, S., Cardiac miR-133a overexpression prevents early cardiac fibrosis in diabetes. J Cell Mol Med 18 (2014), 415–421.
62. [62] Shyu, K.G., Wang, B.W., Wu, G.J., Lin, C.M., Chang, H., Mechanical stretch via transforming growth factor-beta1 activates microRNA208a to regulate endoglin expression in cultured rat cardiac myoblasts. Eur J Heart Fail 15 (2013), 36–45.
63. [63] Montgomery, R.L., Hullinger, T.G., Semus, H.M., Dickinson, B.A., Seto, A.G., Lynch, J.M., Stack, C., Latimer, P.A., Olson, E.N., van Rooij, E., Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation 124 (2011), 1537–1547.
64. [64] Tijsen, A.J., van der Made, I., van den Hoogenhof, M.M., Wijnen, W.J., van Deel, E.D., de Groot, N.E., Alekseev, S., Fluiter, K., Schroen, B., Goumans, M.J., van der Velden, J., Duncker, D.J., Pinto, Y.M., Creemers, E.E., The microRNA-15 family inhibits the TGFβ-pathway in the heart. Cardiovasc Res 104 (2014), 61–71.
65. [65] Porrello, E.R., Mahmoud, A.I., Simpson, E., Johnson, B.A., Grinsfelder, D., Canseco, D., Mammen, P.P., Rothermel, B.A., Olson, E.N., Sadek, H.A., Regulation of neonatal and adult mammalian heart regeneration by the miR-15 family. Proc Natl Acad Sci U S A 110 (2013), 187–192.
66. [66] Hullinger, T.G., Montgomery, R.L., Seto, A.G., Dickinson, B.A., Semus, H.M., Lynch, J.M., Dalby, C.M., Robinson, K., Stack, C., Latimer, P.A., Hare, J.M., Olson, E.N., van Rooij, E., Inhibition of miR-15 protects against cardiac ischemic injury. Circ Res 110 (2012), 71–81.
67. [67] Nagalingam, R.S., Sundaresan, N.R., Noor, M., Gupta, M.P., Solaro, R.J., Gupta, M., Deficiency of cardiomyocyte-specific microRNA-378 contributes to the development of cardiac fibrosis involving a transforming growth factor β (TGFβ1)-dependent paracrine mechanism. J Biol Chem 289 (2014), 27199–27214.
68. [68] Jazbutyte, V., Fiedler, J., Kneitz, S., Galuppo, P., Just, A., Holzmann, A., Bauersachs, J., Thum, T., MicroRNA-22 increases senescence and activates cardiac fibroblasts in the aging heart. Age (Dordr) 35 (2013), 747–762.
69. [69] Huang, Z.P., Chen, J., Seok, H.Y., Zhang, Z., Kataoka, M., Hu, X., Wang, D.Z., MicroRNA-22 regulates cardiac hypertrophy and remodeling in response to stress. Circ Res 112 (2013), 1234–1243.
70. [70] Li, Y., Saldanha, S.N., Tollefsbol, T.O., Impact of epigenetic dietary compounds on transgenerational prevention of human diseases. AAPS J 16 (2014), 27–36.
71. [71] Zullo, A., Casamassimi, A., Mancini, F.P., Napoli, C., Cardiovascular disease and transgenerational epigenetic effects. Tollefsbol, T., (eds.) Transgenerational epigenetics evidence and debate, 2013, Elsevier, Amsterdam, 321–341.
72. [72] Aagaard-Tillery, K.M., Grove, K., Bishop, J., Ke, X., Fu, Q., McKnight, R., Lane, R.H., Developmental origins of disease and determinants of chromatin structure: maternal diet modifies the primate fetal epigenome. J Mol Endocrinol 41 (2008), 91–102.
73. [73] Guedes, E.C., França, G.S., Lino, C.A., Koyama, F.C., Moreira, L.D., Alexandre, J.G., Barreto-Chaves, M.L., Galante, P.A., Diniz, G.P., MicroRNA expression signature is altered in the cardiac remodeling induced by high fat diets. J Cell Physiol 231 (2016), 1771–1783.
74. [74] Kuwabara, Y., Horie, T., Baba, O., Watanabe, S., Nishiga, M., Usami, S., Izuhara, M., Nakao, T., Nishino, T., Otsu, K., Kita, T., Kimura, T., Ono, K., MicroRNA-451 exacerbates lipotoxicity in cardiac myocytes and high-fat diet-induced cardiac hypertrophy in mice through suppression of the LKB1/AMPK pathway. Circ Res 116 (2015), 279–288.
75. [75] Ceylan-Isik, A.F., Kandadi, M.R., Xu, X., Hua, Y., Chicco, A.J., Ren, J., Nair, S., Apelin administration ameliorates high fat diet-induced cardiac hypertrophy and contractile dysfunction. J Mol Cell Cardiol 63 (2013), 4–13.
76. [76] Bugyei-Twum, A., Advani, A., Advani, S.L., Zhang, Y., Thai, K., Kelly, D.J., Connelly, K.A., High glucose induces Smad activation via the transcriptional coregulator p300 and contributes to cardiac fibrosis and hypertrophy. Cardiovasc Diabetol, 13, 2014, 89.
77. [77] Li, H.L., Liu, C., de Couto, G., Ouzounian, M., Sun, M., Wang, A.B., Huang, Y., He, C.W., Shi, Y., Chen, X., Nghiem, M.P., Liu, Y., Chen, M., Dawood, F., Fukuoka, M., et al. Curcumin prevents and reverses murine cardiac hypertrophy. J Clin Invest 118 (2008), 879–893.
78. [78] Pang, X.F., Zhang, L.H., Bai, F., Wang, N.P., Garner, R.E., McKallip, R.J., Zhao, Z.Q., Attenuation of myocardial fibrosis with curcumin is mediated by modulating expression of angiotensin II AT1/AT2 receptors and ACE2 in rats. Drug Des Devel Ther 9 (2015), 6043–6054.
79. [79] Meng, Z., Yu, X.H., Chen, J., Li, L., Li, S., Curcumin attenuates cardiac fibrosis in spontaneously hypertensive rats through PPAR-γ activation. Acta Pharmacol Sin 35 (2014), 1247–1256.
80. [80] Qian, Y., Zhong, P., Liang, D., Xu, Z., Skibba, M., Zeng, C., Li, X., Wei, T., Wu, L., Liang, G., A newly designed curcumin analog Y20 mitigates cardiac injury via anti-inflammatory and anti-oxidant actions in obese rats. PLOS ONE, 10, 2015, e0120215.
81. [81] Palfi, A., Bartha, E., Copf, L., Mark, L., Gallyas, F. Jr., Veres, B., Kalman, E., Pajor, L., Toth, K., Ohmacht, R., Sumegi, B., Alcohol-free red wine inhibits isoproterenol-induced cardiac remodeling in rats by the regulation of Akt1 and protein kinase C alpha/beta II. J Nutr Biochem 20 (2009), 418–425.
82. [82] Sutra, T., Oiry, C., Azay-Milhau, J., Youl, E., Magous, R., Teissèdre, P.L., Cristol, J.P., Cros, G., Preventive effects of nutritional doses of polyphenolic molecules on cardiac fibrosis associated with metabolic syndrome: involvement of osteopontin and oxidative stress. J Agric Food Chem 56 (2008), 11683–11687.
83. [83] Pechánová, O., Bernátová, I., Babál, P., Martínez, M.C., Kyselá, S., Stvrtina, S., Andriantsitohaina, R., Red wine polyphenols prevent cardiovascular alterations in L-NAME-induced hypertension. J Hypertens 22 (2004), 1551–1559.
84. [84] Metes-Kosik, N., Luptak, I., Dibello, P.M., Handy, D.E., Tang, S.S., Zhi, H., Qin, F., Jacobsen, D.W., Loscalzo, J., Joseph, J., Both selenium deficiency and modest selenium supplementation lead to myocardial fibrosis in mice via effects on redox-methylation balance. Mol Nutr Food Res 56 (2012), 1812–1824.
85. [85] Wang, C., Zheng, J., Sun, J., Wang, Y., Xia, R., Yin, Q., Chen, W., Xu, Z., Liao, J., Zhang, B., Gao, F., Endogenous contrast T1rho cardiac magnetic resonance for myocardial fibrosis in hypertrophic cardiomyopathy patients. J Cardiol 66 (2015), 520–526.
86. [86] Napoli, C., Zullo, A., Picascia, A., Infante, T., Mancini, F.P., Recent advances in proteomic technologies applied to cardiovascular disease. J Cell Biochem 114 (2013), 7–20.
87. [87] Wang, X., Liu, T., Zhao, Z., Li, G., Noncoding RNA in cardiac fibrosis. Int J Cardiol 187 (2015), 365–368.
88. [88] Mai, L., Xiao, L., Huang, Y., Mai, W., Novel microRNAs involved in regulation of cardiac fibrosis. Int J Cardiol 192 (2015), 14–15.
89. [89] Bronnum, H., Andersen, D.C., Schneider, M., Sandberg, M.B., Eskildsen, T., Nielsen, S.B., Kalluri, R., Sheikh, S.P., miR-21 promotes fibrogenic epithelial-to-mesenchymal transition of epicardial mesothelial cells involving programmed cell death 4 and sprouty-1. PLoS ONE, 8, 2013, e56280.
90. [90] Wei, C., Kim, I.K., Kumar, S., Jayasinghe, S., Hong, N., Castoldi, G., Catalucci, D., Jones, W.K., Gupta, S., NF-kappaB mediated miR-26a regulation in cardiac fibrosis. J Cell Physiol 228 (2013), 1433–1442.
91. [91] Bernardo, B.C., Gao, X.M., Winbanks, C.E., Boey, E.J., Tham, Y.K., Kiriazis, H., Gregorevic, P., Obad, S., Kauppinen, S., Du, X.J., Lin, R.C., McMullen, J.R., Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function. Proc Natl Acad Sci U S A 109 (2012), 17615–17620.
92. [92] Pan, Z., Sun, X., Shan, H., Wang, N., Wang, J., Ren, J., Feng, S., Xie, L., Lu, C., Yuan, Y., Zhang, Y., Wang, Y., Lu, Y., Yang, B., MicroRNA-101 inhibited postinfarct cardiac fibrosis and improved left ventricular compliance via the FBJ osteosarcoma oncogene/transforming growth factor-beta1 pathway. Circulation 126 (2012), 840–850.
93. [93] Jiang, X., Ning, Q., Wang, J., Angiotensin II induced differentially expressed microRNAs in adult rat cardiac fibroblasts. J Physiol Sci 63 (2013), 31–38.
94. [94] Tao, H., Chen, Z.W., Yang, J.J., Shi, K.H., MicroRNA-29a suppresses cardiac fibroblasts proliferation via targeting VEGF-A/MAPK signal pathway. Int J Biol Macromol 88 (2016), 414–423.
95. [95] Napoli, C., Infante, T., Casamassimi, A., Maternal-foetal epigenetic interactions in the beginning of cardiovascular damage. Cardiovasc Res 92 (2015), 367–374.
96. [96] Napoli, C., Crudele, V., Soricelli, A., Al-Omran, M., Vitale, N., Infante, T., Mancini, F.P., Primary prevention of atherosclerosis: a clinical challenge for the reversal of epigenetic mechanisms?. Circulation 125 (2012), 2363–2373.
97. [97] Grimaldi, V., Vietri, M.T., Schiano, C., Picascia, A., De Pascale, M.R., Fiorito, C., Casamassimi, A., Napoli, C., Epigenetic reprogramming in atherosclerosis. Curr Atheroscler Rep., 17, 2015, 476.